Immatics

Immatics, based in Tübingen and Houston and listed as IMTX, is a TCR-T company whose PRAME-directed anzu-cel, or IMA203, is in the phase 3 SUPRAME trial in melanoma, with a launch targeted for 2027. In its phase 1b, anzu-cel gave a 54 percent confirmed response rate with a median duration of response of 12.1 months in PD-1-pretreated melanoma; SUPRAME, with a progression-free survival primary endpoint, is on track to complete randomisation by the end of 2026 with its analysis expected to trigger in 2026, and the company also develops TCR bispecifics it calls TCER. OnCo links it to melanoma and sarcomas, to TCR-T cell therapy, to PRAME as a target, and to the Comprehensive Cancer Center Tübingen-Stuttgart. Whether an engineered TCR therapy can become a standard option in a common solid tumour is the question SUPRAME will answer. The PRAME target page carries the competitive field.